10
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Infiltration of Gastric Cancer Stroma by Tumor-Infiltrating Lymphocytes Correlates with Mechanistic Target of Rapamycin Signaling

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: We investigated whether the infiltration of tumor-infiltrating lymphocytes (TILs) in gastric cancer (GC), as evaluated by hematoxylin and eosin (H&E) staining, could be a prognostic marker. We also explored on the relationship between TILs and mechanistic target of rapamycin (mTOR) and how it regulates immune effector responses in GC. Methods: A total of 183 patients with available data on TIL were included. TIL infiltration was evaluated using H&E staining. We also conducted immunohistochemistry to determine mTOR expression. Results: Positive TIL infiltration was defined as TILs ≥20%. There were 72 (39.3%) and 111 (60.7%) positive and negative cases, respectively. TILs positivity significantly correlated with both absence of lymph node metastasis ( p = 0.037) and negative p-mTOR expression ( p = 0.040). TIL infiltration correlated with a significantly better overall ( p = 0.046) and disease-free ( p = 0.020) survival. Conclusion: mTOR possibly suppresses TIL infiltration in GC. H&E staining is an effective tool for evaluating the immune status of GC patients. H&E staining may be used in clinical practice to monitor treatment response in GC.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          2023
          August 2023
          14 June 2023
          : 101
          : 8
          : 520-526
          Affiliations
          [_a] aDepartment of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
          [_b] bDepartment of Diagnostic Pathology, Gunma University Graduate School of Medicine, Maebashi, Japan
          [_c] cDepartment of Pathology, Japanese Red Cross Maebashi Hospital, Maebashi, Japan
          [_d] dDivision of Integrated Oncology Research, Gunma University Initiative for Advanced Research, Maebashi, Japan
          Author information
          https://orcid.org/0000-0002-8667-158X
          https://orcid.org/0000-0002-9531-5157
          https://orcid.org/0000-0003-0860-3132
          https://orcid.org/0000-0003-3284-4796
          Article
          531475 Oncology 2023;101:520–526
          10.1159/000531475
          37315539
          9b6cdcd7-b50c-4f7e-8e1b-afd022e9b3df
          © 2023 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 04 February 2023
          : 02 June 2023
          Page count
          Figures: 3, Tables: 2, Pages: 7
          Funding
          The authors disclose no grant support.
          Categories
          Clinical Study

          Medicine
          Mechanistic target of rapamycin,Gastric cancer,Tumor-infiltrating lymphocytes
          Medicine
          Mechanistic target of rapamycin, Gastric cancer, Tumor-infiltrating lymphocytes

          Comments

          Comment on this article